胃癌术后放化疗与单纯化疗随机对照试验结果的荟萃分析

doi:10.3760/cma.j.issn.1004-4221.2014.01.001

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的采用偱证医学荟萃分析的方法比较胃癌术后放化疗与单纯化疗的RCT结果差异。方法检索中国期刊全文数据库、维普、中国生物医学文献数据库，Cochrane图书馆、PubMed和EMBASE，纳入胃癌术后放化疗及单纯化疗的RCT研究。汇总数据采用RevMan5.2及Stata12软件进行分析。两组间差异采用RR及95%CI描述。结果根据纳入和排除标准，最终纳入11个1 143例患者的RCT资料。荟萃分析结果显示胃癌术后放化疗比单纯化疗的1、2、3年OS率高（RR=1.20，95%CI=1.10～1.30，P=0.00；RR=1.34，95%CI=1.16～1.56，P=0.00；RR=2.62，95%CI=1.72～3.97，P=0.00）；3、5年PFS率也高（RR=1.10，95%CI=1.00～1.21，P=0.04；RR=1.27，95%CI=1.02～1.60，P=0.04)。胃肠道反应、肝功能损害、骨髓移植及手足综合征等3~4级发生率低且两组相似（P=0.03~0.78）。结论胃癌术后放化疗可提高生存时间，且患者对药物的耐受性尚可。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李小奇
	姜雷
	赵达
	甘亮亮
	邓成辉
	关泉林

关键词 ：胃肿瘤/综合疗法, 术后放化疗法, 术后化学疗法, 随机对照试验, 荟萃分析

Abstract：Objective To compare the efficacy and safety between postoperative chemoradiotherapy and postoperative chemotherapy alone in patients with gastric cancer by a meta-analysis of randomized controlled trials (RCTs). Methods Chinese Scientific Journal Full-Text Database (January 1979-June 2013), VIP (January 1989-June 2013), Chinese Biomedical Literature Database (January 1978-June 2013), Cochrane Library (Issue 6, 2013), PubMed (January 1966-June 2013), and EMBASE (January 1974-June 2013) were searched to identify RCTs of postoperative chemoradiotherapy versus chemotherapy alone in patients with gastric cancer. The obtained data were analyzed using RevMan 5.2 and Stata 12. The difference between two groups was estimated by calculating the risk ratio (RR) with 95% confidence interval (CI). Results A total of 1 143 patients from 11 RCTs were included in the meta-analysis according to the inclusion and exclusion criteria. Our results showed that postoperative chemoradiotherapy significantly increased 1-, 2-, and 3-year overall survival rates (RR=1.20, 95% CI=1.10-1.30, P=0.00; RR=1.34, 95% CI=1.16-1.56, P=0.00; RR=2.62, 95% CI=1.72-3.97, P=0.00) and 3- and 5-year disease-free survival rates (RR=1.10, 95% CI=1.00-1.21, P=0.04; RR=1.27, 95% CI=1.02-1.60, P=0.04). The incidence of grade 3 or 4 gastrointestinal tract reactions, liver function impairment, bone marrow suppression, and hand-foot syndrome was low and showed little difference between two groups (P=0.03-0.78). Conclusions Postoperative chemoradiotherapy can prolong the survival of patients with gastric cancer, and the patients have good tolerance to chemotherapy drugs.

Key words： Stomach neoplasms/combined modality therapy Postoperative radiochemotherapy Postoperative chemotherapy Randomized controlled trial Meta-analysis

收稿日期: 2013-08-01

基金资助:中央高校基本科研业务费专项资金(lzujbky-2013-160)

通讯作者: 关泉林, Email: guanquanlin2013@163.com

引用本文:

李小奇,姜雷,赵达等. 胃癌术后放化疗与单纯化疗随机对照试验结果的荟萃分析[J]. 中华放射肿瘤学杂志, 2014, 23(1): 1-4.

Li Xiaoqi,Jiang Lei,Zhao Da et al. Randomized controlled trials of postoperative chemoradiotherapy versus chemotherapy alone in patients with gastric cancer: a meta-analysis[J]. Chinese Journal of Radiation Oncology, 2014, 23(1): 1-4.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2014.01.001 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2014/V23/I1/1

[1] Siegel R, Naishadham D, Jemal A.Cancer statistics, 2012[J].CA Cancer J Clin,2012,62:10-29.
[2] 郑朝旭, 郑荣寿, 陈万青.中国2009年胃癌发病与死亡分析[J].中国肿瘤,2013,22:327-332.
[3] Ali Z, Deng Y, Ma C.Progress of research in gastric cancer[J].J Nanosci Nanotechnol,2012,12:8241-8248.
[4] Ajani JA, Bentrem DJ, Besh S, et al.Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines[J].J Natl Compr Canc Netw,2013,11:531-546.
[5] Fiorica F, Cartei F, Enea M, et al.The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data[J].Cancer Treat Rev,2007,33:729-740.
[6] Ohri N, Garg MK, Aparo S, et al.Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis[J].Int J Radiat Oncol Biol Phys,2013,86:330-335.
[7] Jansen EP, Boot H, van de Velde CJ, et al.Can adjuvant ch emoradiotherapy replace extended lymph node dissection in gastric cancer?[J] Recent Results Cancer Res,2012,196:229-240.
[8] Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].N Engl J Med,2006,355:11-20.
[9] Smalley SR, Benedetti JK,Haller DG, et al.Updated analysis of SWOG-directed intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J].J Clin Oncol,2012,30:2327-2333.
[10] Kim S, Lim DH, Lee J, et al.An observational study sugge sting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach[J].Int J Radiat Oncol Biol Phys,2005,63:1279-1285.
[11] Leong CN, Chung HT, Lee KM, et al.Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma[J].Cancer J,2008, 14:269-275.
[12] Lim DH, Kim DY, Kang MK, et al.Patterns of failure in gas tric carcinoma after D2 gastrectomy and chemoradio therapy: a radiation oncologist's view[J].Br J Cancer,2004,91:11-17.
[13] Kim TH, Park SR, Ryu KW, et al.Phase 3 trial of posto perative chemotherapy alone versus chemoradiation therapy in Ⅲ-Ⅳstage gastric cancer treated with R0 gastrectomy and D2 lymph node dissection[J].Int J Radiat Oncol Biol Phys,2012,84:585-592.
[14] Kwon HC, Kim MC, Kim KH, et al.Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection[J].Asia Pac J Clin Oncol,2010,6:278-285.
[15] Lee J, Limdo H, Kim S, et al.Phase Ⅲ trial comparingc apecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecita bine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J].J Clin Oncol,2012,30:268- 273.
[16] Yu C, Yu R, Zhu W, et al.Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery[J].J Cancer Res Clin Oncol,2012,138:255-259.
[17] 陈亚楠, 左云,宋宇.进展期胃癌术后调强放疗序贯5-Fu微泵联合吡柔比星和奥沙利铂化疗[J].肿瘤学杂志,2012,18:336-338.
[18] 郭红伟, 靳秀丽,魏桂芳,等.进展期胃癌术后多西他赛联合卡培他宾化疗及同步放疗的临床研究[J].中国癌症杂志,2010,20:699-702.
[19] 胡蓉环, 刘安文,蔡婧,等.进展期胃癌D2根治术后同步放化疗的临床观察[J].实用临床医学,2012,13:41-43.
[20] 涂向阳.局部晚期胃癌术后同步放化疗临床研究[J].实用肿瘤杂志,2011,26:62-64.
[21] 杨治花, 折虹,闫钢,等.局部进展期胃癌根治术后同期放化疗与单纯化疗的临床比较[J].中华放射肿瘤学杂志,2012,21:252-254.
[22] 赵景胜, 陈群,向志碧,等.45例局部晚期胃癌术后辅助同步放化疗临床研究[J].肿瘤学杂志,2010,16:760-763.
[23] 赵立新, 梁越,董宝珠,等.晚期胃癌D2根治术后辅助放化疗的临床研究[J].现代中西医结合杂志,2012,21:1283-1285.
[24] Schmidt B,Yoon SS.D1 versus D2 lymphadenectomy for gastric cancer[J].J Surg Oncol,2013,107:259-264.
[25] Abbasi SY, Taani HE, Saad A, et al.Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomes[J]. Gastrointest Cancer Res,2011,4:122-127.
[26] Vereczkei A.Gastric surgery.Magy Seb,2012,65:108-115.
[27] Smalley SR, Gunderson L, Tepper J, et al.Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation[J].Int J Radiat Oncol Biol Phys,2002,52:283-293.
[28] Gomceli I, Demiriz B,Tez M.Gastric carcinogenesis[J].World J Gastro enterol,2012,37:5164-5170.
[29] Nakashima S, Hatanaka N, Yoshikawa Y, et al.Long-term survival of a case of advanced cancer of the esopha gogastric junction with complet e response to low-dose 5-fluorouracil and cisplatin chemo therapy[J].Gan To Kagaku Ryoho,2012,39:1559-1561.
[30] Chao CKS, Perez CA, Brady LW. Radiation oncology:management decisions[M]. 3rd ed. New York: Lippincott Williams & Wilkins,2011:21-23.
[31] Ohtsu A, Yoshida S, Saijo N.Disparities in gastric cancer chemothera py between the East and West[J].J Clin Oncol,2006,24:2188-2196.
[32] 郭林, 成红艳.胃癌标准D2根治术后同步放化疗临床研究进展[J].东南大学学报(医学版),2012(4):530-532.